Drug Trial News

RSS

Teplizumab type I diabetes prevention study now enrolls younger children

A type I diabetes prevention study that is part of the TrialNet program at Vanderbilt is now enrolling children as young as 8 years old, following an FDA decision allowing the drug Teplizumab (anti-CD3) to be used in younger children.

1 Aug 2012

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

InSite Vision Incorporated today announced that patient enrollment has begun in the first Phase 3 clinical trial of BromSite (ISV-303) for the reduction of pain and inflammation after cataract surgery.

31 Jul 2012

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

Array BioPharma today announced that ARRY-797 met its primary endpoint in a randomized, placebo-controlled and active-controlled (oxycodone ER) Phase 2 clinical trial in 157 osteoarthritis patients suffering from moderate to severe knee pain despite the use of non-steroidal anti-inflammatory drugs (NSAIDs).

31 Jul 2012

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

GenSpera, Inc. announced that the U.S. Food and Drug Administration (FDA) has cleared for initiation a Phase II human clinical trial of its lead compound, G-202, in the treatment of prostate cancer patients who have failed prior hormonal therapy.

31 Jul 2012

Latrepirdine appears effective in treating Alzheimer's disease in animals

An international team of scientists led by researchers at Mount Sinai School Medicine have discovered that a drug that had previously yielded conflicting results in clinical trials for Alzheimer's disease effectively stopped the progression of memory deterioration and brain pathology in mouse models of early stage Alzheimer's disease.

31 Jul 2012

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

Pfizer Inc. announced today top-line results from ORAL Start (A3921069), a Phase 3 study of the investigational agent tofacitinib, a novel, oral Janus kinase (JAK) inhibitor for the treatment of adults with moderate-to-severe active rheumatoid arthritis (RA).

31 Jul 2012

New drug shows promise for Long QT syndrome

Long QT syndrome, which results from genetic mutation or certain medications, can cause the heart to beat chaotically and the affected person to die suddenly. The chaotic heartbeat is due to abnormal electrical activity in the heart. In an electrocardiogram test, this abnormality appears as a wider-than-normal QT interval, a pattern of "hills" in a map of peaks and valleys corresponding to the heart contracting and relaxing.

30 Jul 2012

FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas

Senesco Technologies, Inc. reported today that it was informed on July 26th that the U.S. Food and Drug Administration has granted orphan-drug designation for the company's lead drug candidate SNS01-T for treatment of both mantle cell lymphoma and diffuse large B-cell lymphoma.

30 Jul 2012

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Tonix Pharmaceuticals Holding Corp., a specialty pharmaceutical company developing therapies for challenging disorders of the central nervous system, including fibromyalgia syndrome and post-traumatic stress disorder, announces that the clinical portion of a human study of a solution version of TNX-102 2.4 mg sublingual tablets has completed.

30 Jul 2012

Positive results from XIAFLEX phase IIIb multicord trial for Dupuytren's contracture

Auxilium Pharmaceuticals, Inc., a specialty biopharmaceutical company, today announced positive top-line data from its open-label phase IIIb trial evaluating XIAFLEX for the treatment of adult Dupuytren's contracture patients with multiple palpable cords. The Company enrolled 60 patients at eight sites throughout the U.S. and Australia.

30 Jul 2012

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Vermillion, Inc., a leading molecular diagnostics company, today announced positive results from a new prospective, multi-center clinical study of its ovarian cancer diagnostic OVA1.

30 Jul 2012

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Advaxis, Inc.,, a leader in developing the next generation of immunotherapies for cancer and infectious diseases, presented updated preliminary data from an ongoing randomized Phase 2 trial of ADXS-HPV being conducted in India in women with recurrent/refractory cervical cancer who have failed previous cytotoxic therapy.

30 Jul 2012

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Further analyses of the landmark NIH-funded treatment-as-prevention study (HPTN 052) have found that providing antiretroviral treatment to HIV-infected individuals earlier, when their immune systems are healthier, delays AIDS-related health events, such as chronic herpes simplex virus and tuberculosis, as well as death. Additionally, researchers found that earlier HIV treatment is also cost-effective because it increases survival, prevents costly opportunistic infections and averts transmission of the virus to uninfected individuals.

30 Jul 2012

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Scientists at the Singapore Eye Research Institute (SERI) and Nanyang Technological University (NTU) have developed an innovative way to combat post-surgical scarring for glaucoma patients.

30 Jul 2012

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine, IMA901, have been published in Nature Medicine.

30 Jul 2012

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Genentech, a member of the Roche Group, today announced that the BREVACTA study of ACTEMRA (tocilizumab) given as a subcutaneous (SC) injection to patients with rheumatoid arthritis (RA) met its primary endpoint.

28 Jul 2012

Economist articles, blog examine research presented at AIDS 2012 conference

The Economist on Friday published two articles from Saturday's print edition regarding the XIX International AIDS Conference (AIDS 2012). One article states that "few areas of international affairs have seen more recent success than the fight against AIDS," and discusses advancements in HIV treatment research and availability.

28 Jul 2012

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

"The world's first vaccine against dengue fever, being developed by French drugmaker Sanofi SA, protected against three of the virus's four strains in a keenly awaited clinical trial in Thailand," the company announced on Wednesday, Reuters reports.

28 Jul 2012

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

ARIAD Pharmaceuticals, Inc. today announced the initiation of the randomized Phase 3 trial of ponatinib, its investigational pan-BCR-ABL inhibitor, in adult patients with newly diagnosed chronic myeloid leukemia (CML).

28 Jul 2012

Rituximab also benefits patients with kidney disorder

A drug commonly used to treat immune disorders such as lymphoma and arthritis also benefits patients with an immune disorder of the kidneys that can lead to kidney failure, according to a study appearing in an upcoming issue of new study in the Journal of the American Society of Nephrology (JASN).

28 Jul 2012

Drug Trial News

Teplizumab type I diabetes prevention study now enrolls younger children

InSite Vision commences enrollment in BromSite Phase 3 clinical trial

Array BioPharma announces positive results from ARRY-797 Phase 2 trial on osteoarthritis

GenSpera receives FDA clearance to commence G-202 Phase II trial in prostate cancer

Latrepirdine appears effective in treating Alzheimer's disease in animals

Top-line results from Pfizer's tofacitinib Phase 3 study on moderate-to-severe active RA

New drug shows promise for Long QT syndrome

FDA grants Senesco's SNS01-T orphan-drug designation to treat lymphomas

Encouraging results from Tonix TNX-102 SL clinical trial for fibromyalgia syndrome

Positive results from XIAFLEX phase IIIb multicord trial for Dupuytren's contracture

Positive results from Vermillion OVA500 multi-center study for ovarian cancer

Advaxis reports continued positive patient survival pattern in ADXS-HPV Phase 2 cervical cancer trial

Early ART treatment delays AIDS-related health events in HIV-infected individuals

Scientists discover new way to combat post-surgical scarring for glaucoma patients

Paper highlights clinical and immunological activity of immatics’ IMA901 in renal cell carcinoma

Genentech's BREVACTA study of ACTEMRA on rheumatoid arthritis meets primary endpoint

Economist articles, blog examine research presented at AIDS 2012 conference

Experimental dengue vaccine protects against 3 of 4 viral strains, study results show

ARIAD Pharmaceuticals commences ponatinib Phase 3 trial in newly diagnosed CML

Rituximab also benefits patients with kidney disorder

Flow chemistry, AI, and NMR: A next-gen approach to scalable API production

Digital pathology and the PathoVerse: A conversation with Dr. Singh

Bioprocess Efficiency with Cell Density Monitoring

Latest News